San Diego based startup Acurion has closed an oversubscribed $4.3 million seed financing round (exceeding its $4 million target). The round was led by TK & Partners with participation from Mesa Verde Venture Partners, the National Foundation for Cancer Research, the Asian Fund for Cancer Research, Bootstrap Ventures, and other investors. The funds will support clinical validation, platform development, regulatory preparation, and commercialization of its OncoGaze AI platform.
Glimpse:
Acurion’s OncoGaze platform uses AI-powered image analysis to detect clinically relevant genomic biomarkers directly from routine pathology slides, helping oncologists select personalized therapy options without the need for additional tissue or expensive molecular testing. The technology works across all cancer types and enables faster, more accessible precision oncology decisions in standard clinical workflows.
Acurion, a San Diego based precision oncology technology company, has successfully raised $4.3 million in an oversubscribed seed financing round. The investment was led by TK & Partners and attracted participation from prominent healthcare focused investors including Mesa Verde Venture Partners, the National Foundation for Cancer Research, the Asian Fund for Cancer Research, Bootstrap Ventures, and others.
The company is developing OncoGaze, an innovative AI-driven platform that analyses standard pathology slides used in everyday clinical practice to extract actionable genomic biomarker insights. Unlike traditional genomic testing that often requires extra tissue samples and specialised labs, OncoGaze delivers real time biomarker detection across all cancer types, making precision medicine more scalable, cost effective, and accessible to a wider range of patients and healthcare settings.
The fresh capital will be used to advance clinical validation studies, enhance the platform’s capabilities, prepare for regulatory approvals, and accelerate commercialization efforts. Acurion’s technology is built on foundational research in mutational signatures and aims to integrate seamlessly into existing clinical workflows, helping oncologists make faster and more informed treatment decisions.
This funding round reflects growing investor confidence in AI solutions that can bridge the gap between complex science and practical, everyday cancer care.
“AI has the potential to reshape how we detect and act on cancer biomarkers. What stood out to us about Acurion is their ability to translate complex science into a solution that fits directly into existing clinical workflows. This is the kind of innovation that can expand access to precision oncology at scale.”
By
HB Team
Related News
